Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Resonance SpecialtiesBOM:524218 -2.92%70 EBITDA Margin % is 26.07% as of Mar. 2026, which is 83% above its 10-year median of 14.24. GuruFocus rates BOM:524218 with a GF Score™ of 70/100 and a GF Value™ of ₹140.97 (Fairly Valued). The stock has 7 warning signs investors should review. Among 1,577 Chemicals companies, Resonance Specialties ranks better than 75.21% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Resonance Specialties EBITDA Margin % Related Terms
Resonance Specialties EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Resonance Specialties's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Chemicals subindustry, Resonance Specialties's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Resonance Specialties EBITDA Margin % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Resonance Specialties's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Resonance Specialties's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Resonance Specialties (BOM:524218) has a EBITDA Margin % of 26.07% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Resonance Specialties and its competitors. This is 83% above median its historical median of 14.24. Over the past decade, Resonance Specialties' EBITDA Margin % has ranged from 4.24 to 24.32. According to the industry distribution chart, Resonance Specialties ranks #391 out of 1577 companies in the Chemicals industry, placing it in the top 24.8%.
Is Resonance Specialties' EBITDA Margin % too high?
Resonance Specialties' current EBITDA Margin % of 26.07% is 83% above median its 10-year median of 14.24. Over the past 10 years, this metric has ranged from a low of 4.24 to a high of 24.32. The Chemicals industry median EBITDA Margin % is 9.64. Resonance Specialties' value of 26.07% is 170.4% above this industry median. Based on the distribution chart, Resonance Specialties ranks #391 out of 1577 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, Resonance Specialties has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Resonance Specialties' EBITDA Margin % compare to DOW?
According to the Chemicals industry distribution chart, Resonance Specialties ranks #391 out of 1577 companies for EBITDA Margin %. This places Resonance Specialties in the top 25% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 9.64. Resonance Specialties' value of 26.07% is 170.4% above this benchmark. Historically, Resonance Specialties' own EBITDA Margin % has ranged from 4.24 to 24.32 over the past decade. While the company's 10-year median is 14.24 vs. the industry median of 9.64, Resonance Specialties has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Chemicals company?
The median EBITDA Margin % among Chemicals companies is 9.64, based on 1,577 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Resonance Specialties's current EBITDA Margin % of 26.07% is 170.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Resonance Specialties and its competitors. For the Chemicals industry, the median EBITDA Margin % is 9.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Resonance Specialties's current EBITDA Margin % is 26.07%, which is 83% above median its own 10-year median of 14.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resonance Specialties stock overvalued right now?
Based on GuruFocus' analysis, Resonance Specialties (BOM:524218) is currently considered Fairly Valued. The stock's GF Value™ is ₹140.97, compared to a current price of ₹144.80 — trading 2.7% above its estimated fair value. The current EBITDA Margin % is 26.07%, which is 83% above median its 10-year median of 14.24 and 170.4% above the Chemicals industry median of 9.64. Resonance Specialties' overall GF Score™ is 70/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Resonance Specialties (BOM:524218), the current EBITDA Margin % is 26.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Resonance Specialties (BOM:524218) Overvalued in 2026?
Based on GuruFocus' analysis, Resonance Specialties stock appears to be overvalued.
The current stock price of ₹144.80 is trading 2.7% above its estimated GF Value™ of ₹140.97.
GuruFocus considers Resonance Specialties to be Fairly Valued.
Key valuation signals for BOM:524218:
EBITDA Margin %: 26.07% (83% above median its 10-year median of 14.24)
GF Value™: ₹140.97 vs. price of ₹144.80 (2.7% above fair value)
Industry Position: 170.4% above the Chemicals median (#391 of 1577)
No single metric tells the full story. See the BOM:524218 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Resonance Specialties Ltd is engaged in the manufacturing of chemicals. The company is manufacturing Pyridine, Picoline, Cynopyridine, and derivatives of the same. Bulk drugs and nutritional products are tolls converted. It delivers pyridine and related products. The company has only one segment which is Chemical Manufacturing. The company also manufactures anti-tuberculosis products such as Isoniazid. Geographically. It operates in India and Outside India. The majority of segment revenue is from Outside India.
70GF Score
Get the complete analysis for BOM:524218
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524218 has been successfully added to your 
